Faisal Mahmood

Dr. Faisal Mahmood is an Associate Professor at Harvard Medical School and the Division of Computational Pathology at Brigham and Women’s Hospital and Massachusetts General Hospital. He is a full member of the Dana-Farber Cancer Institute / Harvard Cancer Center ; an Associate Member of the Broad Institute of Harvard and MIT. His laboratory works on developing foundation models, generative and agentic AI algorithms, methods, and techniques for healthcare with a particular focus on disease diagnosis, prognosis and therapeutic response prediction. Dr. Mahmood’s lab has developed several widely used methods and algorithms for digital and computational pathology, and his lab’s work has been published in major scientific journals. He is also a principal investigator on several large NIH and ARPA-H grants. Dr. Mahmood is also the Scientific Co-Founder of Modella AI a company with a focus on developing generative and agentic AI tools for healthcare.

Weihong Tan

Professor Weihong Tan earned his Ph.D. in physical chemistry at the University of Michigan in 1993. Currently, he is the director of Hangzhou Institute of Medicine, Chinese Academy of Sciences, the dean of the Zhejiang Cancer Hospital. He is also the director of the State Key Laboratory of Chemo/Biosensing and Chemometrics, and distinguished professor of chemistry and biology at Hunan University, and the director of the Institute of Molecular Medicine at Renji Hospital and Shanghai Jiao Tong University. He served as a University Distinguished Professor and a V.T. and Louis Jackson Professor at the University of Florida for more than 20 years. Professor Tan’s research is in the general area of molecular medicine, bioanalytical chemistry, and chemical biology. He specializes in aptamer research, DNA nanotechnology, and cancer theranostics. He has received many awards and honors, including the Second Prize of the State Natural Science Award in 2014 and 2020, the Award in Spectrochemical Analysis from the American Chemical Society in 2018, the Prize for Scientific and Technological Progress, Ho Leung Ho Lee Foundation in 2018, the Ralph Adams Award for Bioanalytical chemistry and The Pittsburgh Analytical Chemistry Award in 2019, Britton Chance Award in 2024.

Kun-Hsing Yu

Jinsong Liu

Da Liu

Mr. Da Liu is an accomplished investment professional with over two decades of experience spanning clinical pharmacy, corporate healthcare leadership, and life sciences venture capital. Beginning his career as a clinical pharmacist in New York, he later held executive roles in China and now serves as a global life sciences investor based in Hong Kong.

Known for bridging deep clinical insight with strategic investment acumen, Mr. Liu focuses on supporting technologies that drive paradigm shifts, improve healthcare accessibility, and solve key industry challenges. He has a strong track record of identifying high-potential ventures and helping them grow into market leaders. His notable investments include GenScript, Legend Biotech, and Belkin Vision, which was acquired by Alcon in 2024. In 2021, he led an $87 million financing round for MiRXES, a Singapore company in the diagnostics sector. This was the largest life sciences fundraising in Southeast Asia at the time and led to MiRXES’s successful IPO in 2025.

Mr. Liu is the author of two award-winning books on life sciences investment and serves on the Committee on Innovation, Technology and Industry Development of Hong Kong SAR. His leadership and foresight continue to shape the future of diagnostics and healthcare innovation across Asia and beyond.

Ruijiang Li

Kenneth Philbrick

Lichao Sun

Yuan Li

Daljeet Bansal

Daljeet Bansal BMedSci PhD, is the Operations Director of the National Pathology Imaging Cooperative (NPIC) and oversees both the delivery of the program and leads on research partnerships. NPIC builds on the existing fully digital lab at Leeds and will create a globally leading infrastructure for digital pathology and Artificial Intelligence research. NPIC aims to deploy digital pathology scanners across over 40 hospitals across England, scanning over 2.3m images per year and generating 3 Petabytes of image data per year. NPIC considers the entire life cycle of AI development including deployment of digital pathology, data ethics, data sharing practices, patient and public engagement, interoperability and standards (DICOM), quality assurance, clinical validation and AI clinical exemplars for the real world evaluation of digital pathology.

Chao-Hui Huang

Chih-Hong Wang is currently the Operations Manager of Pathology at Regeneron Pharmaceuticals, Inc. He earned his PhD in Molecular and Cellular Pathology from the University of North Carolina at Chapel Hill in 2010 and completed his postdoctoral fellowship at the University of California San Diego. With over a decade of experience in histology and pathology studies, his research primarily focuses on cardiovascular diseases and hematology. He has published 17 papers in these fields. Before joining Regeneron in 2022, he held faculty positions in the Department of Physiology & Hypertension and Kidney Center at Tulane University, and the Department of Internal Medicine, Division of Nephropathy at UMICH. He later served as a principal scientist of the histopathology team at TrueBinding Inc. He is driven by the mission to assist scientists and pathologists in achieving fulfillment and a sense of belonging in their study projects. He utilizes digital pathology to foster collaboration on significant projects in preclinical drug development studies.

Chen Li

Chee Leong Cheng

Dr. Cheng is the Head and Senior Consultant at the Department of Anatomical Pathology, Singapore General Hospital (SGH) and Director of Computational and Digital Pathology at Division of Pathology, SGH and Singhealth Pathology Academic Clinical Programme. He specializes in haematolymphoid pathology, digital pathology, and healthcare informatics, leading digital enablement, AI and data science applications in pathology.

His academic qualifications include M.B.B.S. (NUS), F.R.C.P.A. (Australasia), F.R.C.Path (UK), and multiple Masters degrees in Bioinformatics (Johns Hopkins University), Molecular Pathology (Queen Mary University of London), and Health Informatics (University of Edinburgh).

Dr. Cheng is an Assistant Professor at Duke-NUS Medical School and has authored several peer-reviewed publications in pathology, genomics, and AI applications. He contributed to the WHO Classification of Haematolymphoid Tumours and has secured grants for AI-driven pathology innovation. He is an executive member of the Asian Society of Digital Pathology (Treasurer, since 2024) and the Association of Pathologist Singapore (IT Secretary, since 2015), as well as Associate Editor of Pathology (RCPA) and International Editorial Board Member for Journal of Pathology Informatics.

Jinmiao Chen

Dr. Jinmiao Chen is an Associate Professor at Duke-NUS Medical School, NUS Yong Loo Lin School of Medicine, and a Senior Principal Investigator at A*STAR, Singapore. Her research lab specializes in AI-powered single-cell and spatial omics analysis for precision medicine, with a particular focus on developing AI algorithms and omics databases. Recognized as a Highly Cited Researcher from 2020 to 2024 and selected as an EMBO Global Investigator in 2023, Dr. Chen holds a bachelor’s degree in computer science from Sun Yat-sen University, China, and a PhD in AI and Computational Biology from Nanyang Technological University, Singapore. Following her PhD, she joined A*STAR as a postdoctoral researcher before establishing her own research lab.

Yuan Ke

Jing Zhang

Dan Su

Yueping Liu

Dr. Liu holds prominent leadership roles in numerous national and provincial academic organizations, including:

• Chair of the Breast Tumor Group under the Chinese Anti-Cancer Association Committee on Tumor Pathology
• Vice Chair of the CSCO Tumor Pathology Expert Committee
• Executive Member of the Pathology Section, Chinese Medical Doctor Association
• Chair of the Pathology Section, Hebei Medical Doctor Association

Zou Hong

• Professor of Pathology/Chief Physician, Doctor, Doctoral Supervisor
• Standing Committee Member of the Pathology Committee of China Association for Medical Devices Industry
• Vice President of the Pathology Branch of Zhejiang Provincial Medical Association and Vice Director of the Digital Medicine Branch

In recent years, the research has been focused on tumor pathology and molecular diagnosis, tumor and metabolism, and nanodrug therapy for tumors. She has presided over four projects of the National Natural Science Foundation of China, published 150 academic papers (67 of which were indexed by SCI), and published 22 SCI academic papers as the first or corresponding author. She has also won two second prizes for provincial scientific and technological progress (second place), one second prize in the Provincial Higher Education Teachers; Teaching Innovation Competition, and an award for teaching and academic innovation.

Xiaowen GE

Yuhong Li

Desiree Abdurachim

Shuhao Wang

Liansheng Wang

Hao Chen

Yuhao Yi

Dr. Yuhao Yi is a researcher in the Institute of Clinical Pathology, West China Hospital, Sichuan University. He received his Ph.D. degree in Computer Science from Fudan University, China, in 2019. From 2019 to 2020, he was a postdoc in the Computer Science Department at Rensselaer Polytechnic Institute, USA, and from 2020 to 2022, he was a postdoc in EECS at KTH Royal Institute of Technology. He started his work at Sichuan University as a researcher in August 2022 in the College of Computer Science and is now affiliated with the Institute of Clinical Pathology. He has broad research interests ranging from foundations in algorithm design to trends in artificial intelligence. Currently, his research focuses on pathology image processing, distributed learning and optimization algorithms, and calibration of large multimodal language models in pathology applications. He has published more than 20 papers in conferences including AAAI, IJCAI, WWW, IJCNN, and journals such as IEEE Trans. Inf. Theory (TIT), SIAM J. Control Optim. (SICON), IEEE TCYB, and TCNS. His work is supported in part by the Young Scientists Fund of the National Natural Science Foundation of China.

Qin Wu

Joshua Li Jing Xi,

Mark Frushone

David Brettle

Prof. David Brettle is the Chief Scientific Officer at Leeds Teaching Hospitals NHS Trust, the Quality Theme Lead for NPIC, and an honorary professor at the University of Salford. Prior to this he was the Head of Medical Physics and Engineering at Leeds Teaching Hospitals for 11 years. During this time, he completed a term as President of the institute of Physics in Engineering and Medicine. In 2022 he received a lifetime achievement award from the Chief Scientific Officer for NHS England.

His current role includes the professional lead for the Healthcare Scientists in Leeds; research into image quality and the development of quality tools in digital pathology at NPIC; and leading on innovation and technology for the two new hospitals being built in Leeds.

His background is in radiology physics and his digital imaging experience spans over 30 years. Early work included developing some of the first digital mammograms and algorithms. From this work themes around image probity, digital display, imaging system evaluation and psychophysics have been developed and are re-applied in digital pathology through his role in NPIC.

Anita Nangia

Dr. (Prof) Anita Nangia MBBS MD (Pathology), is the Medical Director of Optra Scan, a pioneering digital pathology company providing advanced digital slide scanners & AI -driven solutions. She supervises and evaluates creation of new AI driven in-demand pathology solutions at Optra Scan and leads on research partnerships.

Professor Nangia earned her MD in Pathology from the prestigious Delhi University, India in 1997. She served as Medical Faculty and Director Professor at the renowned Lady Hardinge Medical College and associated Hospitals, New Delhi, India for more than two decades. She was instrumental in setting up immuno-oncology, immunohistochemistry and F.I.S.H platforms at her Institution. Dr. Nangia has deep interest in immuno-oncology and onco-pathology, and her research focuses on biomarkers and tumour microenvironment in breast, GIT, gynaecological and paediatric tumours.

Her vast clinical and research experience is now guiding and collaborating, with the dedicated and hardworking team of professionals at Optra Scan, to integrate cutting edge technology and AI into streamlining lab workflows and advance patient diagnostics.

She was conferred the Eminent Scientist category and Membership to the National Academy of Medical Sciences, India in November 2024. She and her team also received the Best Research Team award 2024, Indian Council of Medical Research, New Delhi, India.

Nao Umeno

For over 90 years, Fujifilm has found #ValueFromInnovation through expanding its portfolio to represent a broad spectrum of industries including medical and life sciences, electronic, chemical, graphic arts, information systems, industrial products, broadcast, data storage, and photography.
In 1936, the company launched its healthcare business with x-ray film, and haven’t stopped innovating since. The world’s first digital X-ray imaging diagnostic system, the “FCR”, was developed and launched in 1981 and 1983, respectively. Celebrated as a “trailblazer of the digital era,” the FCR played a pivotal role in driving the now-continuing transition toward digitalization in the field of healthcare. Today, its solutions span diagnostic, enterprise, endoscopic, and surgical imaging powered by medical AI, as well as in-vitro diagnostics, regenerative medicine, and life sciences. By supporting every step of the patient’s health journey, from prevention to diagnosis and treatment, the company remains committed to continually innovating to help healthcare organizations like yours make the world a healthier place.
Fujifilm’s Group Purpose, “Giving our world more smiles” underscores its commitment to bring diverse ideas, unique capabilities, and extraordinary people together to change the world.